Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zuclopenthixol
Drug ID BADD_D02398
Description Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.
Indications and Usage Used in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
Marketing Status approved; investigational
ATC Code N05AF05
DrugBank ID DB01624
KEGG ID D03556
MeSH ID D003006
PubChem ID 5311507
TTD Drug ID D0I8LU
NDC Product Code Not Available
UNII 47ISU063SG
Synonyms Clopenthixol | Zuclopenthixol | alpha-Clopenthixol | alpha Clopenthixol | Cisordinol
Chemical Information
Molecular Formula C22H25ClN2OS
CAS Registry Number 53772-83-1
SMILES C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Menopausal symptoms21.02.02.002---
Menstrual disorder21.01.01.004---
Menstruation irregular05.05.01.008; 21.01.01.005--
Micturition disorder20.02.02.005---
Migraine17.14.02.001; 24.03.05.003---
Miosis06.05.03.003; 17.02.11.002---
Muscle rigidity15.05.04.001; 17.05.02.005---
Myalgia15.05.02.001--
Mydriasis06.05.03.004; 17.02.11.003---
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.003---
Neutropenia01.02.03.004---
Nightmare19.02.03.003---
Oculogyric crisis06.05.02.002; 17.01.03.002---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Opisthotonus17.01.03.005---
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancytopenia01.03.03.003---
Paraesthesia17.02.06.005; 23.03.03.094--
Parkinsonism17.01.05.003---
Photosensitivity reaction23.03.09.003--
Polyuria20.02.03.002---
Pregnancy18.08.02.004---
Pregnancy test false positive13.10.05.003---
Priapism21.03.01.005; 24.04.12.007---
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene